How I treat myelofibrosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm.
• Characterized by clonal proliferation, aberrant kinase signaling, and cytokine release.
• Current treatments offer limited survival benefits.

Observation:

• Janus kinase (JAK)2 mutation discovery led to targeted therapies.
• JAK inhibitors, such as ruxolitinib, are effective for MF symptoms and splenomegaly.
• Ruxolitinib has improved the therapeutic landscape but lacks disease-modifying effects.

Findings:

• Allogeneic stem cell transplantation is the only curative option for MF.
• Transplantation is limited by morbidity and mortality, reserved for high-risk patients.
• Combinations of JAK inhibitors with other agents are under investigation.

Implications:

• Further research is needed to develop disease-modifying therapies for MF.
• Investigating novel drugs and combination therapies holds promise for improved outcomes.
• Optimizing treatment strategies is crucial for managing myelofibrosis.